Clinical trials: Methotrexate
RHEUMATOID ARTHRITIS
Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient
Compare the efficacy of adding small doses of prednisolone (10 mg) daily to the efficacy of adding one of the available anti TNF in the treatment of methotrexate inadequate responder rheumatoid arthritis patient.
- Trial name
- NCT01724268
- Testing
- Pred + Meth, Anti TNF + Meth
- Where
- Qatar
- Volunteers
- 80 people
- Sponsor
- Hamad Medical Corporation
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate
This multicenter study with a randomized, double-blind, parallel-group phase will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy in…
- Trial name
- NCT01587989
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 13 sites in Austria
- Volunteers
- 77 people
- Sponsor
- Hoffmann-La Roche
Psoriasis, Arthritis, Psoriatic
Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis
The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.
- Trial name
- NCT00161655
- Testing
- Etanercept, Methotrexate
- Where
- 8 sites in Denmark, Finland and 2 more
- Volunteers
- 60 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriasis
A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to compare the safety and efficacy of risankizumab to methotrexate in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT03219437
- Testing
- risankizumab, methotrexate
- Where
- 11 sites in Brazil
- Volunteers
- 104 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT03139136
- Testing
- MBS2320
- Where
- 3 sites in Georgia, Moldova and 1 more
- Volunteers
- 121 people
- Sponsor
- Modern Biosciences Ltd
Arthritis, Psoriatic
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this…
- Trial name
- OPAL BALANCE (NCT01976364)
- Testing
- Tofacitinib, Methotrexate
- Where
- 153 sites in United States, Australia and 14 more
- Volunteers
- 686 people
- Sponsor
- Pfizer
Psoriasis
MAP Study: Methotrexate and Adalimumab in Psoriasis
Assess the efficacy and safety of ADA compared to ADA/MTX in patient with Psoriasis. Compare Anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on combination ADA and MTX.
- Trial name
- MAP (NCT03217734)
- Testing
- Adalimumab, Methotrexate
- Where
- 4 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jeffrey J Crowley MD
Rheumatoid Arthritis
Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)
The purpose of this study objective will be to evaluate the efficacy and safety of etanercept 50 mg BIW in RA subjects who showed a sub-optimal response to standard dose etanercept (50 mg QW) and concomitant methotrexate therapy.
- Trial name
- NCT00115219
- Testing
- Etanercept
- Volunteers
- 200 people
- Sponsor
- Amgen
Arthritis, Rheumatoid
Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis
The purpose of this study is to evaluate the safety and efficacy of TAK-715, twice daily (BID), in the treatment of rheumatoid arthritis signs and symptoms in patients with a partial response to methotrexate.
- Trial name
- NCT00760864
- Testing
- TAK-715 and methotrexate, Methotrexate
- Volunteers
- 432 people
- Sponsor
- Takeda
Rheumatoid Arthritis
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an…
- Trial name
- NCT04909801
- Testing
- Abatacept, Adalimumab, Methotrexate
- Where
- 75 sites in United States, Argentina and 12 more
- Volunteers
- 338 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis
This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA).
- Trial name
- OPTIMA (NCT00420927)
- Testing
- adalimumab, methotrexate
- Where
- 170 sites in United States, Argentina and 19 more
- Volunteers
- 1,032 people
- Sponsor
- Abbott
Rheumatoid Arthritis
A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis
This open-label randomized 2arm study will investigate the pharmacokinetics, pharmacodynamics, efficacy and safety of subcutaneously administered tocilizumab in patients with rheumatoid arthritis who have shown an inadequate…
- Trial name
- NCT00965653
- Testing
- folic acid, methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 7 sites in Canada, New Zealand and 1 more
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Systemic Lupus Erythematosus
Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
This pooled analysis will assess data from the Phase 3 belimumab registration studies BLISS-52 (aka BEL110752) and BLISS-76 (aka BEL110751). The analysis was pre-planned and agreed prior to the unblinding of either study.
- Trial name
- NCT01914770
- Testing
- Belimumab 1 mg/kg, Belimumab 10 mg/kg
- Volunteers
- 1,016 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate
PLX3397 is a selective inhibitor of Fms and Kit activity. The objective of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interaction (DDI) of orally administered PLX3397 during…
- Trial name
- NCT01090570
- Testing
- PLX3397
- Where
- 5 sites in United States
- Sponsor
- Plexxikon
Wegeners Granulomatosis
Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis
The aim of the study is to assess the efficacy (superiority testing) of gusperimus compared to conventional treatment in patients with a relapse of Wegener Granulomatosis with or without ongoing steroids, and/or immunosuppressive…
- Trial name
- SPARROW (NCT01446211)
- Testing
- Gusperimus + glucocorticoids, cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
- Where
- Czechia
- Volunteers
- 4 people
- Sponsor
- Nordic Pharma SAS
Rheumatoid Arthritis
The Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis
The aim of this study is to evaluate the efficacy and safety of Fang yi qing Feng shi granules in subjects with Rheumatoid Arthritis.
- Trial name
- NCT02029599
- Testing
- Fang yi qing feng shi granule, Methotrexate, Acetaminophen tablets
- Where
- 5 sites in China
- Volunteers
- 240 people
- Sponsor
- Maoxiang Group Jilin Pharmaceutical Co., Ltd.
Healthy Volunteer
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
This study is a Phase I, single center, randomized (Parts 1 and 2 only), open-label, 3 part study. Parts 1 and 2 are 2-way crossover, with 1-fixed sequence, 3-period designs to investigate the effect of formulation, food and…
- Trial name
- QCL117578 (NCT02699710)
- Testing
- Folic Acid, GDC-0853, Methotrexate
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
This 3 arm study will compare the safety and efficacy, with respect to a reduction in signs and symptoms and prevention of joint damage, of tocilizumab versus placebo, both in combination with methotrexate (MTX) in patients with…
- Trial name
- NCT00106535
- Testing
- tocilizumab [RoActemra/Actemra], Methotrexate
- Where
- 152 sites in United States, Australia and 14 more
- Volunteers
- 1,196 people
- Sponsor
- Hoffmann-La Roche
Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Multi-center, open-label, single arm study of asciminib in participants aged ≥1 year to ≤30 years old with r/r Ph+ or ABL-class Ph-like ALL. This study will have 2 parts: Part 1 dose escalation and Part 2 dose expansion.
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT07387926
- Testing
- Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone
- Where
- 4 sites in Australia, Israel and 2 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
The RESOLVE study is a two-part, randomized, double-blind, multi-center, placebo-controlled study of the safety, dose-range finding confirmation, and efficacy of 4 (Part A) and 12 weeks (Part B) of treatment with AP1189 in adult…
- Trial name
- RESOLVE (NCT05604885)
- Testing
- AP1189, 60 mg, AP1189, 80 mg, AP1189, 100 mg
- Where
- Moldova
- Volunteers
- 125 people
- Sponsor
- SynAct Pharma Aps